Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Nebius Group remains a core AI play, with strong management and the potential for multi-year value creation. Learn more about ...

Cantor Fitzgerald initiated coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research report ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...